PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
EBIT growth exceeding 1.5x Healthcare median of 38.13%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
-121.69%
Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-139.60%
Negative net income growth while Healthcare median is -1.51%. Seth Klarman would investigate factors dragging net income down.
-131.82%
Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-131.82%
Negative diluted EPS growth while Healthcare median is 0.20%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.70%
Negative OCF growth while Healthcare median is -20.64%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-31.70%
Negative FCF growth while Healthcare median is -20.95%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
95.37%
OCF/share CAGR exceeding 1.5x Healthcare median of 18.08% over 10 years. Joel Greenblatt would verify if a unique competitive moat underlies these cash flows.
75.95%
5Y OCF/share growth exceeding 1.5x Healthcare median of 16.38%. Joel Greenblatt might see a strong moat or efficient cost structure driving outperformance.
7.00%
Below 50% of Healthcare median. Jim Chanos would suspect fundamental problems or inadequate monetization of sales in the near term.
81.58%
Net income/share CAGR exceeding 1.5x Healthcare median of 38.71% over a decade. Joel Greenblatt might see a standout compounder of earnings.
47.75%
5Y net income/share CAGR > 1.5x Healthcare median of 28.90%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
-122.09%
Negative 3Y CAGR while Healthcare median is 28.95%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
-94.45%
Negative 10Y equity/share growth while Healthcare median is 11.80%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
58.16%
5Y equity/share CAGR of 58.16% while Healthcare median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
-73.50%
Negative 3Y equity/share growth while Healthcare median is -23.31%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-21.56%
Negative BV/share change while Healthcare median is -3.47%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-8.90%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
60.05%
R&D growth of 60.05% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
231.77%
SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.